Coriolis Pharma appoints formulation and drug development expert Bruce Kerwin to scientific advisory board
Coriolis Pharma appoints formulation and drug development expert Bruce Kerwin to scientific advisory board
Bruce Kerwin brings extensive industry and scientific expertise to the company and will consult Coriolis and its clients with a focus on the US market
Martinsried-Munich, Germany, December 6th, 2022 – Coriolis Pharma, a globally operating service provider and one of the world leaders in formulation research and development of (bio)pharmaceutical drugs, including cell and gene therapy products and vaccines, is strengthening its scientific advisory board with the appointment of Bruce Kerwin.
Kerwin joins the scientific advisory board of Coriolis as a recognized industry expert in formulation and drug development with 30 years of experience leading project teams through multiple stages of development from pre-IND to commercialization. In previous positions at Umoja BioPharma, Just-Evotec Biologics, Amgen and Baxter Hemoglobin Therapeutics, Kerwin was responsible for research and strategies developing novel solutions to formulation problems such as high viscosity, high concentration, co-formulated proteins, and process development and formulation of viruses.
During his industry carreer he has published more than 60 peer-reviewed articles. As scientific advisor at Coriolis, Kerwin will bring his extensive industry and scientific expertise to the company and will serve as an additional point of contact for Coriolis’ customers and prospects in North America alongside the Coriolis business development team.
In close collaboration with Coriolis´ Science and Technology Unit, Kerwin will support the design and implementation of innovative formulation strategies and concepts for biopharmaceuticals and new entities, such as cell-based or virus-based products. In addition, Kerwin will represent the company at national and international scientific meetings.
“We are very excited to have Bruce on board who will be able to contribute greatly to our company during this time of rapid growth," said Silvia Steyrer-Gruber, Chief Executive Officer at Coriolis. "Bruce's extensive knowledge in formulation and drug development from early- to late-stage products and through the approval process will be essential to achieve our goal of expanding our activities and presence in North America in the coming years."
With Bruce Kerwin Coriolis expands its scientific advisory board to ten members in total, including the most renowned specialists in biopharmaceutical formulation development and characterisation. All of them are actively involved throughout client projects and contribute with advice to a successful outcome for the clients.
About Coriolis Pharma
Coriolis Pharma is a globally operating contract research organization and one of the world leaders in formulation research and development of (bio)pharmaceutical drugs, including cell and gene therapy products and vaccines. The company’s offering includes early and late-stage formulation development for liquid and lyophilized drug products, lyophilization process development and analytical development under R&D and GMP. Non-GMP manufacturing services for a wide range of products complete the service portfolio.
It is the vision of Coriolis to revolutionize the development process of biopharmaceutical drugs by integrating innovative digital formulation approaches from drug development to commercial products. Coriolis Pharma thereby enables future therapies to be made available to humankind efficiently and on time.
With its interdisciplinary team of highly skilled scientists and an expert scientific advisory board, Coriolis provides cutting-edge services and tailor-made solutions for its clients. Founded in 2008 and headquartered in Martinsried near Munich, Germany, Coriolis currently employs around 200 employees from over 35 nations around the world.
For more information visit https://www.coriolis-pharma.com.
